DiagnosTear
Screening and Monitoring Kit for Dry Eye Syndrome
Company Overview
Snapshot
Founded in September 2013 by Eran Eilat, DiagnosTear operates with 1–10 employees. The company has raised $4.58M across five funding rounds from two investors. In December 2024, DiagnosTear became publicly listed on the CSE.
Business overview
DiagnosTear specializes in developing technology for the diagnosis, treatment, and monitoring of dry eye syndrome. Its core product, the TeaRx assay, utilizes reagents that create color reactions with tear film to provide a semi-quantitative assessment of parameters defining the syndrome. This technology assists in diagnosis, informs treatment selection, and enables ongoing monitoring and screening by examining up to five varieties of tear fluid through a simple device. DiagnosTear operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices, serving healthcare providers globally.
Strategic signal
In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform, a significant move that enables needle-free blood diagnostics. This strategic acquisition expands the company's diagnostic capabilities beyond tear-based analysis, signaling a broader ambition in non-invasive medical diagnostics and potentially opening new market segments for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is DiagnosTear's primary focus?
- DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome, developing an assay designed to facilitate diagnosis, treatment, and monitoring by examining parameters in tear fluid.
- When did DiagnosTear go public?
- DiagnosTear became publicly listed on the Canadian Securities Exchange (CSE) in December 2024.
- What is the TeaRx assay?
- The TeaRx assay is DiagnosTear's core product, based on reagents that create color reactions with tear film for semi-quantitative assessment of dry eye syndrome parameters, aiding in diagnosis and treatment selection.
- What was a recent significant strategic development for DiagnosTear?
- In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform, enabling needle-free blood diagnostics.
- Has DiagnosTear initiated any collaborations for its TeaRx product?
- In November 2025, DiagnosTear Technologies announced the initiation of a collaboration with LV Prasad Eye Institute for advancing the clinical validation of its TeaRx Red Eye Diagnostic Test.